Award of Share Options

RNS Number : 9210B
hVIVO plc
16 January 2018
 

For immediate release 7.00am: 16 January 2018

 

HVIVO PLC

("hVIVO" or the "Company")

 

Award of Share Options

 

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that on 15 January 2018 it awarded the following options over ordinary shares of 5.0p each in the Company to Liam Eves:

 

Name

Position

Number of Share Options Awarded

Exercise price per Share

Date of Vesting

Percentage of issued ordinary share capital

Liam Eves

Executive Vice President, Humatics

136,364

5.0p

20 December 2020

0.17%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the persons discharging managerial responsibilities/persons closely associated

a)

Name

Liam Eves

2

Reason for the notification

a)

Position/ status

Executive Vice President, Humatics - A person closely associated with Kym Denny, Chief Executive Officer of the Company

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

hVIVO plc

b)

Legal Entity Identifier

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Options over Ordinary Shares of 5 pence each

 

 

ISIN: GB00B6ZM0X53

b)

Nature of the transaction

Award of options over Ordinary Shares in the Company

c)

Currency

GBP

d)

Price(s) and volume(s)

Director

Exercise Price (p)

Volume

Liam Eves

5.0

136,364

 

e)

Aggregated information

- Aggregated volume

- Exercise price

 

 

136,364 options over Ordinary Shares

5.0p

f)

Date of the transaction

15 January 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

For further information please contact:

 

hVIVO plc

+44 207 756 1300

Kym Denny (Chief Executive Officer)


Graham Yeatman (Chief Financial & Business Officer)




Media Enquiries

+1 919 710 9658

Susan Flood (Head of Marketing)




Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black / Michael Burke (Corporate Broking)




FTI Consulting


Simon Conway / Victoria Foster Mitchell (UK)

+44 203 727 1000

John Capodanno / Evan Smith (US)

+1 212 850 5705

 

 

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHUVRVRWVAAAAR

Companies

Hvivo (HVO)
UK 100

Latest directors dealings